BIONXT ACCELERATES CLADRIBINE ODF CLINICAL AND COMMERCIALIZATION STRATEGY FOR MULTIPLE SCLEROSIS TREAMENT
Nov 20, 2023
VANCOUVER, BC – November 20, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTCQB: BNXTF / FSE: BXT) is pleased to...